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Abstract
Cell-permeable peptides (CPPs) have been widely studied as an attractive drug delivery
system to deliver therapeutic macromolecules such as DNA, RNA, and protein into cells.
However, its clinical application is still limited and controversial due to the lack of a complete
understanding of delivery efficiency in target cells. Previously we identified and character-
ized the novel and superior CPP, named dNP2, and here we comparatively analyzed intra-
cellular delivery efficiency of dNP2 and TAT in various immune cells of mouse spleen to
demonstrate their cell type preference. dNP2- or TAT-conjugated fluorescent proteins were
most efficiently taken up by phagocytic cells such as dendritic cells and macrophages while
little protein uptake was seen by lymphocytes including T cells, B cells, and NK cells. Inter-
estingly CD8+ lymphoid dendritic cells and CD62LloCD44hi memory like T cell subsets
showed significantly better uptake efficiency in vitro and in vivo relative to other dendritic
cells or T cells, respectively. In addition, activated macrophages, T cells, and B cells took up
the proteins more efficiently relative to when in the resting state. Importantly, only dNP2, not
TAT, shows significant intracellular protein delivery efficiency in vivo. Collectively, this study
provides important information regarding heterogeneous intracellular delivery efficiency of
CPPs such as dNP2 and TAT with cell type preference in the spleen needed for its applica-
tion in phagocytic cells or activated immune cells.
Introduction
Cell permeable peptides (CPPs), either identified from various native proteins or designed as
synthetic peptides, are being utilized to deliver therapeutic macromolecules into cells in vitro
and in vivo [1, 2]. Since the TAT protein from HIV was found to localize to the nucleus and
cytoplasm of cultured cells without the need for transfection reagents [3], the intracellular
delivery of proteins by cell permeable peptides has been intensively studied. Arginine or lysine
rich cationic peptides such as TAT [4], Antp [5], VP22 [6] and R9 [7] have been used over the
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last few decades to deliver various macromolecular cargos including siRNA [8, 9], oligonucleo-
tides [10], peptides [11], and transcription factors [12, 13] to alter cellular behavior and modu-
late disease pathogenesis as a macromolecular therapeutics. Cationic CPPs bind to negatively
charged cell membrane molecules such as proteoglycans on glycoproteins or negatively
charged membrane lipid molecules and trigger endocytosis by the cells to uptake the CPP-
cargo complex [14, 15]. Recently, human protein derived CPPs have been identified such as
VectoCell [16], Lactoferin [17], Hph-1 [18], Sim-2 [11], LPIN [19], 2IL-1a [20] to minimize
possible immunogenicity and toxicity in vivo. However, it has been demonstrated that almost
all cells are permeable to CPPs without specificity, which remains one of the major challenges
to the use of CPPs as an advantageous drug delivery tool [2]. Although a significant number of
clinical trials have been performed using TAT, there are as of yet no available FDA approved
CPP-drugs for any human disease. Here, we hypothesized that the understanding of heteroge-
neous delivery efficiency by a CPP would increase the success of CPP drug development.
Recently, we identified the novel human-derived CPP named dNP2 that was efficiently
delivered into primary immune cells including T cells and was even localized to brain tissue
through the blood-brain barrier (BBB) in mice [21]. dNP2 contains amphiphilic amino acids
with basic sequences and hydrophobic amino acids with helix-loop-helix structure as predic-
tion that seem to enhance cellular uptake by endocytosis. To better use this attractive CPP for
valuable drug development, the preferential targeting of dNP2 to specific cells should be inves-
tigated. Therefore, the present study was designed to determine the cell type preference of
dNP2 and TAT in various immune cells of mouse spleen. Enhanced green fluorescent proteins
(EGFPs) fused to CPPs were used to treat splenocytes in vitro and flow cytometric analyses
defined the specific cell types targeted by each CPP protein. In addition, intravenous adminis-
tration of dNP2-EGFP and TAT-EGFP proteins in mice confirmed the in vivo relevance of het-
erogeneous delivery efficiency among the immune cells. Here we found that phagocytic cells
such as DCs and macrophages uptake CPP-proteins more efficiently than lymphocytes. In
addition, activated T cells, B cells, and macrophages are better targeted by CPP then these cells
in their resting state. In addition, in vivo relevance suggests that there is obvious cell type pref-
erence for CPPs with heterogeneous delivery efficiency among various cell population, which
should be considered for therapeutic drug design.
Methods
Cell lines and cell culture
EL4 (mouse lymphoma cell line) and Jurkat (human lymphoma cell line) cells were purchased
from the American Type Culture Collection (ATCC) and cultured using Roswell Park Memo-
rial Institute (RPMI) 1640 media with 10% fetal bovine serum (FBS) and 1% penicillin/strepto-
mycin antibiotics. All cells were maintained in a 5% CO2 incubator at 37stitute (RPMI) 1640
media with 10% fetal bovine seThermo Scientific Hyclone.
Purification of recombinant proteins
Escherichia coli BL21 (DE3) Star pLysS bacterial cells were transformed with CPP-conjugated
fluorescent proteins containing pRSET-b vectors and incubated in 50 ml Lysogeny broth (LB)
containing ampicillin for 12 h at 37l and shaking at 200 rpm. The cultures were transferred to
500 ml of LB media without antibiotics and incubated under the same conditions for another
1–2 h until the optical density at 600 nm (OD600) reached 0.4–0.6. The protein production was
induced using 0.2 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) for 12 h at 20°C with
shaking at 150 rpm. The cells were then harvested by centrifugation at 4arv 5,000 rpm for 15
min and sonicated using the Vibra-cell VCX-130 ultrasonic processor. The supernatants were
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filtered through a 0.45 μM cellulose nitrate syringe filter. The 6-His tag proteins were purified
through Ni-NTA affinity chromatography, and then desalted and buffer exchanged to PBS
containing 10% glycerol using a PD-10 size exclusion column.
Mice
Wild type C57BL/6 mice were purchased from Orient Bio Inc. and bred. All mice were housed
and maintained in a specific pathogen-free animal facility at Hanyang University. All animal
experiments were approved by the Animal Experimentation Ethics Committee of Hanyang
University (Permit Number: 2015–0004, 2015–0006) and were performed in strict accordance
with the guidelines of Institutional Animal Care and Use Committees of Hanyang University.
And all animal research protocols followed the guidelines of Korean Association for Laboratory
Animal Sciences (KALAS). All surgery was performed after CO2 asphyxiation euthanasia pro-
tocol and all efforts were made to minimize suffering.
Splenocyte isolation
Spleens were removed from 6 to 10-week-old mice and chopped with scissors. The chopped tis-
sue was incubated with 2 mg/ml collagenase D at room temperature for 20 min and red blood
cells were depleted by incubating with RBC lysis buffer for 2 min. After centrifugation, the cells
were resuspended in 10% FBS and 1% penicillin/streptomycin containing RPMI media and
counted.
Flow cytometric analysis of CPP-proteins delivery efficiency of in vitro
To analyze the delivery efficiency of CPP-conjugated proteins or CPP-peptide, 5 μM of each
molecule were added to the cells and incubated for 1 h. We used 2.5X105 cells/well for Jurkat
cells and EL4 cells compared with splenocytes and human PBMCs, and 8X106 cells/well for
analyzing various splenocyte cell types. Following incubation, cells were washed twice with
PBS and trypsinized with 0.25% (for cell line) or 0.05% (for primary cells) trypsin-EDTA at
37°C for 10 min. Cells were washed with PBS and stained with fluorochrome-conjugated cell
surface marker specific antibodies and the intracellular delivery efficiency was analyzed using
flow cytometry.
Surface staining for flow cytometric analysis
After incubation with CPP-conjugated molecules, the cells were resuspended in 100 μl anti-
body mixture diluted in PBS and incubated at 4°C for 15 min. To discriminate each cell subset
from the mixed cell population, different antibody combinations were used. For cell type analy-
sis, anti-mouse CD4-PerCP-Cy5.5 (BioLegend, Clone:RM4-5), anti-mouse CD19-PE-Cy7
(BioLegend, Clone:6D5), anti-mouse NK1.1-APC (BioLegend, Clone:PK136), anti-mouse
CD11b-PE-Cy7 (eBioscience, Clone:H57-597), anti-mouse CD11c-APC (eBioscience, Clone:
N418), anti-mouse I-A/I-E-APC-Cy7 (BioLegend, Clone:M5/114.15.2), and anti-mouse F4/
80-PerCP-Cy5.5 (BioLegend, Clone:BM8) were used. Also, anti-mouse CD16/32 (BioLegend,
Clone:93) was used for blocking the Fc receptor. For activated T cell analysis, anti-mouse
CD69-FITC (BioLegend, Clone:H1.2F3), anti-mouse CD4-APC (eBioscience, Clone:GK1.5),
and anti-mouse CD8-PerCP-Cy5.5 (eBioscience, Clone:53–6.7) were used. For activated B cell
analysis, anti-mouse CD86-PE-Cy5 (BioLegend, Clone:GL-1), anti-mouse IgG2a, kappa-iso-
type (BioLegend, Clone:RTK2758), and anti-mouse CD19-PE (BioLegend, Clone:6D5) were
used.
Cell Type Preference of dNP2 and TAT in Various Immune Cells
PLOS ONE | DOI:10.1371/journal.pone.0155689 May 17, 2016 3 / 17
Immune cell activation
To activate splenic T cells, anti-mouse CD3 antibody (2 μg/ml, BD Pharmingen) was coated
onto 96-well plates (BD Falcon) at 3796-well plateellmousesplenocytes were seeded at a density
of 2.5X105 cells/well and incubated overnight at 37 r in a 5% CO2 incubator. To activate B cells,
DCs, or macrophages, isolated splenocytes were cultured in 12-well plates at 4X106 cells/well
with 5 μg/ml (for B cells) or 100 ng/ml (for DCs and macrophages) of Escherichia coli 055:B5
(Sigma-Aldrich) in each well and incubated overnight at 37°C in 5% CO2 incubator.
Flow cytometric analysis of CPP-protein delivery efficiency in vivo
5 mg of EGFP, CPP-EGFP, or PBS was intravenously injected into 6-week-old C57BL/6 female
mice. After 1 h, the mice were sacrificed and spleens were removed for isolating splenocytes
from a single cell suspension. The cells were stained with fluorochrome-conjugated surface
marker specific antibodies and analyzed via flow cytometry.
Statistical analysis
The data were analyzed using one-way ANOVA, two-way ANOVA with multiple comparison
tests or Student’s t-test. p values<0.05 were considered significant. Statistical analysis was per-
formed using Prism 6 (Graphad Software, Inc.).
Results
dNP2- and TAT-proteins are delivered more efficiently to phagocytic
cells than lymphocytes
To determine cell type heterogeneity of dNP2-protein delivery efficiency in various immune
cells of mouse spleen, we treated dNP2-EGFP or TAT-EGFP to splenocytes and intracellular
delivery efficiency was analyzed by flow cytometry by the staining of cell type specific markers
(Fig 1A–1D). The relative mean fluorescent intensity (Relative MFI) represents fold increase
that each MFI is normalized to PBS treated sample (Fig 1B–1D). Statistical significance among
the all groups were comparatively analyzed by one-way ANOVA test with Sidak’s multiple
comparison test (S1 Fig). Both dNP2-EGFP and TAT-EGFP proteins were delivered into
CD11cloCD11bhiF4/80+ macrophages and CD11c+MHCII+ DCs, which are phagocytic and
antigen presenting cells, with significantly higher efficiency than into lymphocytes. In the case
of CD4 T cells, B cells, and NK cells, only dNP2-EGFP showed significant protein delivery effi-
ciency comparing with PBS control while TAT-EGFP did not at 5 μM. This pattern is almost
identical at various incubating time points including 10 min, 30 min, 1 h, 2 h or 6 h (S2 Fig)
and also consistent in the FACS-sorted each cell population (S3 Fig). Interestingly, even EGFP
protein without CPPs was significantly taken up by macrophages as well as DCs although their
relative MFI value is much lower than that of dNP2- or TAT-EGFP treated group (Fig 1B).
These results collectively suggest that phagocytic cells such as macrophages and DCs uptake
CPP-protein more efficiently than lymphocytes, and CPPs such as dNP2 and TAT could sig-
nificantly deliver a cargo protein into those cells to modulate innate immunity including anti-
gen presentation, inflammatory response, etc.
CD8+ dendritic cells are the major cell type to uptake dNP2- and TAT-
proteins
Splenic DCs can be divided into subsets including lymphoid CD8+ DCs, myeloid CD8- DCs,
and plasmacytoid DCs (pDCs) based on different biological characteristics [22–24]. To
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determine CPP-protein delivery efficiency in splenic DC subsets, splenocytes were treated with
red fluorescent dTomato protein fused with dNP2 or TAT (dNP2-dTomato or TAT-dTo-
mato). Intracellular red fluorescence intensity and each DC subset marker were analyzed by
flow cytometry. First, we determined the DC subsets as Siglec H+ pDC, Siglec H-CD11c+-
MHCII+CD8+ lymphoid CD8+ DC, and Siglec H-CD11c+MHCII+CD8- myeloid CD8- DC (Fig
2A). Both TAT-dTomato and dNP2-dTomato proteins were delivered into the CD8+ DCs with
Fig 1. Protein delivery efficiency of dNP2 and TAT in various immune cells. (A) 5 μM of EGFP, TAT-EGFP, dNP2-EGFP, or
PBS were treated to splenocytes from 6-week-old C57BL/6 mice and protein delivery efficiencies were analyzed by flow cytometry
after cell staining with cell type specific markers for CD4+ CD4 T cells, CD19+ B cells, NK1.1+ NK cells, CD11clowCD11bhighF4/80+
macrophages, and MHCII+CD11chigh DCs. (B-D) The experiments were independently repeated three times and are presented as
the relative mean fluorescence intensity (relative MFI). The values were normalized with the MFI of PBS treated samples. Bar graphs
indicate the mean ± s.d. One-way ANOVA was used for statistical analysis and * indicates p<0.05, ** indicates p<0.01, ***
indicates p<0.001, **** indicates p<0.0001.
doi:10.1371/journal.pone.0155689.g001
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significantly higher efficiency relative to CD8- DCs. In addition, pDCs did not uptake CPP-
proteins suggesting that the major cellular subset to uptake CPP-proteins is CD8+ lymphoid
DCs (Fig 2B, 2C and 2D). These results suggest that among the DC subsets, CPP-protein
uptake efficiency is quite variable even in DC subsets and that lymphoid DCs have higher deliv-
ery efficiency than myeloid DCs and pDCs indicating that immunization with CPP-conjugated
antigen cargos would be efficient application using CPPs such as dNP2 and TAT. mDCs also
showed significantly higher delivery efficiency than pDCs (Fig 2C and 2D) suggesting that tar-
geting mDCs by CPP-mediated cargo delivery would be good approaches such as anti-inflam-
matory functions.
Activated lymphocytes uptake dNP2- and TAT-proteins more efficiently
than resting state lymphocytes
Because activated lymphocytes are rapidly proliferating and their membrane proteins are
dynamically regulated, we hypothesized that CPP-proteins would be delivered into activated or
Fig 2. Protein delivery efficiency of dNP2 and TAT among dendritic cell subsets. 5 μM dTomato, TAT-
dTomato, dNP2-dTomato, or PBS were treated to splenocytes from 6-week-old C57BL/6 mice and the cells
were analyzed by flow cytometry. (A) The cells were subdivided into Siglec H-CD11c+MHCII+CD8+ lymphoid
CD8+ DCs, Siglec H-CD11c+MHCII+CD8- myeloid CD8- DCs, and Siglec H+ pDCs. (B) The protein delivery
efficiencies into each subset of DCs were analyzed by flow cytometry. (C-D) The experiments were
independently repeated three times and are presented as the relative mean fluorescence intensity (relative
MFI). The values were normalized with the MFI of PBS treated samples. Bar graphs indicate the mean ± s.d.
and * indicates p<0.01 and *** indicates p<0.0001 from one-way ANOVA with Tukey’s multiple comparison
test (n = 3, (C) F = 59.46, P<0.0001 and (D) F = 134.5, P<0.0001).
doi:10.1371/journal.pone.0155689.g002
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memory-like lymphocytes with higher efficiency relative to resting state lymphocytes. To exam-
ine this, we treated dNP2-dTomato or TAT-dTomato to mouse splenocytes. Then, we at first
subdivided CD4 T cells into CD4+CD62LhiCD44lo naïve CD4 T cells, CD4+CD62LloCD44hi
memory-like CD4 T cells, and CD4+Foxp3+ regulatory T cells by flow cytometry and determined
heterogeneous delivery efficiency by CPP-proteins (Fig 3A). Both dNP2-dTomato and TAT-
dTomato protein, but not dTomato without CPPs, delivery efficiencies were significantly higher
in CD62LloCD44hi memory like activated CD4 T cells than in naïve CD4 T cells and Foxp3+ reg-
ulatory T cells, though the efficiency of dNP2 is much higher than TAT (Fig 3B and 3C). Also
the delivery efficiency was significantly higher in CD4+Foxp3+CD44high cells than that of CD4+-
Foxp3+CD44low cells (Fig 3D and 3E). This result suggests that among the peripheral T cell sub-
sets, CPP-protein delivery efficiency is heterogeneous that memory-like T cells or effector T cells
are preferred by CPP-protein delivery than naïve T cells.
Next, we stimulated isolated mouse splenocytes with plate bound anti-CD3 and anti-CD28
antibodies to determine whether activated CD4 and CD8 T cells would uptake CPP-proteins
more efficiently relative to unstimulated cells (Fig 4A). Both dNP2-EGFP and TAT-EGFP pro-
teins were delivered into activated CD4 and CD8 T cells with significantly higher efficiency
than unstimulated cells (Fig 4C, 4E and 4F). In addition, we stimulated splenocytes with lipo-
polysaccharide (LPS) to examine whether activated B cells would uptake CPP-proteins (Fig
4B). From the results, LPS stimulated B cells uptake dNP2-EGFP and TAT-EGFP proteins
more efficiently than resting B cells (Fig 4D and 4G). These results collectively suggest that
CPPs such as dNP2 and TAT could deliver a cargo protein into activated immune cells with
better efficiency than their resting state that it would be valuable to apply on modulating abnor-
mally activated T or B cell responses in allergic or autoimmune diseases.
Activated macrophages, but not activated dendritic cells, uptake dNP2-
and TAT-proteins more efficiently than resting state
We next examined CPP-protein delivery efficiency in activated macrophages and DCs com-
pared to their resting state. Isolated mouse splenocytes were incubated with or without LPS
stimulation overnight, and then cells were treated with dNP2-EGFP or TAT-EGFP protein for
1 h. The intracellular fluorescence of CD11cloCD11bhiF4/80+ macrophages and CD11c+-
MHCII+ DCs was analyzed by flow cytometry. dNP2-EGFP treated LPS-stimulated macro-
phages showed significantly higher intracellular fluorescence intensity than unstimulated
macrophages and TAT-EGFP treated macrophages also showed a similar delivery pattern even
though the delivery efficiency of dNP2 is much higher than TAT (Fig 5A, 5C and 5E). How-
ever, CPP-protein delivery efficiency in LPS-stimulated DCs was significantly lower than in
resting DCs (Fig 5B, 5D and 5F) possibly due to maturated DCs have less antigen uptake ability
then immature state [25]. Interestingly EGFP without CPPs also shows consistently reduced
protein uptake efficiency by DCs while no difference was observed in macrophages (Fig 5E and
5F). These results suggest that CPP-protein delivery efficiency is more significant in activated
macrophages and immature DCs that it could be valuable to apply it on modulating inflamma-
tory responses mediated by macrophages or on initiating immune responses mediated by DCs.
dNP2- but not TAT-proteins shows consistent cell type preference in
various immune cells of mouse spleen in vivo
Finally, we investigated the applicability of in vitro results in vivo by intravenous administra-
tion of dNP2-EGFP or TAT-EGFP protein in mice. One hour after the intravenous injection of
5 mg dNP2-EGFP or TAT-EGFP into mice, splenocytes were isolated and various immune cell
types were stained with cell type specific marker antibodies (Fig 6A). As consistent with the in
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vitro results, F4/80highCD11bint macrophage cells (blue) are the most major cells to uptake pro-
teins. In addition, delivery efficiency of dNP2-EGFP shows higher delivery efficiency on Ly6C+-
CD11bhigh monocytes than Ly6G+CD11bhigh neutrophils (Fig 6B and 6C). Among the DC
Fig 3. Protein delivery efficiency of dNP2 and TAT on naïve, regulatory, or memory-like CD4 T cells. 5 μM dTomato, TAT-dTomato,
dNP2-dTomato or PBS were treated to splenocytes from Foxp3-GFP transgenic 6-week-old C57BL/6 mice and the cells were analyzed by
flow cytometry. (A) The cells were subdivided into CD4+Foxp3+ regulatory T cells, CD4+CD62LhighCD44low naïve CD4 T cells, and
CD4+CD62LlowCD44high memory-like CD4 T cells by flow cytometry after cell surface marker staining. Also regulatory T cells were
subdivided into Foxp3+CD44low and Foxp3+CD44high cells. (B) The protein delivery efficiencies into each subset of CD4 T cells were
analyzed by flow cytometry. (C) The experiments were independently repeated three times and are presented as the relative mean
fluorescence intensity (relative MFI). The values were normalized with the MFI of PBS treated samples. Bar graphs indicate the mean ± s.d.
and within groups (dTomato, TAT-dTomato and dNP2-dTomato) the differences of means of memory like CD4 T cells and regulatory CD4 T
cells were compared with means of naïve CD4 T cells by two-way ANOVA with Dunnett’s multiple comparison test, * indicates p<0.05 and
**** indicates p<0.0001 (n = 3). (D) The protein delivery efficiencies into each subset of regulatory T cells were analyzed by flow cytometry.
(E) The values were normalized with the MFI of PBS treated samples. Bar graphs indicate the mean ± s.d. and the data were analyzed by
student’s t-test, *indicates p<0.05 (n = 3).
doi:10.1371/journal.pone.0155689.g003
Cell Type Preference of dNP2 and TAT in Various Immune Cells
PLOS ONE | DOI:10.1371/journal.pone.0155689 May 17, 2016 8 / 17
subsets, CD8+ Siglec H- lymphoid DCs (blue) showed higher delivery efficiency than CD8-
Siglec H- myeloid DCs and Siglec H+ pDCs (Fig 6D and 6E). CD62LloCD44hi memory-like
activated cells (red) in both CD4 and CD8 T cells preferentially transduced by dNP2-EGFP
protein relative to CD62LhiCD44lo naïve CD4 and CD8 T cells (Fig 6F and 6G). However,
importantly, TAT-EGFP delivery efficiency was not significant in any cell type population sug-
gesting its limitation for in vivo application. These results suggest that dNP2 efficiently deliver
a cargo protein into various immune cells in vivo with heterogeneous delivery efficiency and
this should be considered for its application design to modulate cellular responses in vivo.
Discussion
In the present study, we characterized and demonstrated cell type preference of the recently
identified human derived BBB-permeable peptide dNP2 [21] and the widely used HIV-derived
CPP, TAT [4, 26] for the uptake of proteins in various immune cells. Both dNP2 and TAT
Fig 4. Protein delivery efficiency of dNP2 and TAT on stimulated or unstimulated T or B cells. Splenocytes from 6-week-old C57BL/6
mice were stimulated with (A) 2 μg/ml anti-mouse CD3 antibody for 12 h or (B) 5 μg/ml LPS for 24 h and additionally incubated in the
presence of 5 μMEGFP, TAT-EGFP, dNP2-EGFP, or PBS for 30 min. (C) The protein delivery efficiency into stimulated or unstimulated
CD4 or CD8 T cells was analyzed by flow cytometry. (D) The protein delivery efficiency into stimulated or unstimulated B cells was analyzed
by flow cytometry. (E-G) The experiments were independently repeated three times and are presented as the mean fluorescence intensity
(MFI). Bar graphs indicate the mean ± s.d. and * indicates p<0.05 and ** indicates p<0.01 from Student’s t-tests (n = 5).
doi:10.1371/journal.pone.0155689.g004
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conjugated fluorescent proteins were more preferentially delivered into phagocytic cells such as
macrophages and DCs relative to lymphocytes. In addition, we confirmed that activated
immune cells including macrophages, T cells, and B cells could uptake proteins with better effi-
ciency relative to their resting state, collectively demonstrating heterogeneous intracellular
delivery efficiency of dNP2 and TAT in vitro and in vivo should be considered for better appli-
cation of these CPPs in disease modulation.
CPPs are generally regarded as a non-specific macromolecular delivery tool, which has been
considered a major disadvantage of CPP usage for therapeutic purposes [27–29]. However,
previous studies reported that the arginine-based CPP r8 peptide, without any targeting
sequences, spontaneously accumulated in xenografted tumors of tumor-bearing nude mice
Fig 5. Protein delivery efficiency of dNP2 and TAT on unstimulated or LPS-stimulated macrophages or dendritic cells.
Splenocytes from 6-week-old C57BL/6 mice were stimulated with 5 μg/ml LPS for 24 h and additionally incubated in the presence of 5 μM
EGFP, TAT-EGFP, dNP2-EGFP, or PBS for 30 min. (A-D) The protein delivery efficiency into stimulated or unstimulated macrophages or
DCs was analyzed by flow cytometry. (E-F) The experiments were independently repeated three times and are presented as the relative
mean fluorescence intensity (relative MFI). The values were normalized with the MFI of PBS treated samples. Bar graphs indicate the
mean ± s.d. and *** indicates p<0.001 from Student’s t-tests (n = 3).
doi:10.1371/journal.pone.0155689.g005
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[30]. Even though the R8 peptide was delivered into normal tissues, it showed a preference for
tumor cells. In addition, in the early days of CPPs, Dowdy et al. reported an odd delivery pat-
tern in spleen tissue in vivo where TAT-β-galactosidase was only detected in red pulp while it
was clearly not detected in white pulp in mice [4]. These studies suggested that CPPs could be
delivered with different efficiencies and specificities depending on target cell type. These previ-
ous results suggest the possibility of cell type preference in various types of cells in vivo.
In the present study, we revealed that both dNP2 and TAT have cell type preference in vari-
ous immune cells. Although the proportion of DCs and macrophages are just 1–2% of total
spleen cells, their CPP-protein uptake efficiency is much dominant compare to the lympho-
cytes including T cells or B cells. This suggests that the phagocytic action or cell’s own charac-
teristics are important in effective CPP-protein delivery. High efficiency in phagocytic cells
including DCs and macrophages also suggest that the application of CPPs such as dNP2 as an
immunization tool to delivery of antigens for vaccine development could be one of the best
approaches. Especially, lymphoid DCs were shown to uptake proteins much more efficiently
than myeloid DCs and plasmacytoid DCs. Previously, it has been reported that lymphoid DCs
have much higher T cell stimulation capacity than myeloid DCs [31]. While, myeloid DCs
have been known as having higher migratory capacity compared with lymphoid DCs [32–34].
In addition, only lymphoid DC can cross-prime cytotoxic T cells in vivo [35]. Thus, lymphoid
DCs which is preferred by CPP-cargo delivery is appropriate target for DC vaccination using
cell-penetrating peptide [36]. Similar to the preference and high delivery efficiency of TAT to
lymphoid DCs in this study, previous studies showed that TAT-conjugated protein antigen
could be a useful DC vaccination methodology for boosting antigen specific CD8 T cell immu-
nity [37, 38]. For example, treatment of the TAT conjugated Leishmania antigen TAT-LACK
to DCs successfully induced Leishmania specific CD8 T cells in vitro while LACK alone could
not [39]. Also, numerous studies reported that DC vaccination is one of the most attractive
approaches for cancer immune therapy using specific cancer antigens [40–43]. TAT conju-
gated breast cancer specific antigen generated cancer specific CD8 T cells and infiltrated into
tumor tissues in vivo [44]. Our study previously showed that dNP2 has higher delivery effi-
ciency relative to TAT suggesting that dNP2 could be more valuable to deliver antigens for the
generation of pathogen or cancer specific immunity.
Macrophages are another potent target cell type for modulating the immune system because
of their high delivery efficiency with both dNP2 and TAT. Macrophages are one of the most
abundant cells existing in every tissue including lymphoid, lung, liver, bone, and brain tissues
with phenotypic diversity [45, 46]. For this reason, the preference of dNP2-protein delivery to
macrophages could be a useful tool for modulating macrophage functions regarding inflamma-
tion, disease pathogenesis, or bone remodeling.
Both dNP2 and TAT conjugated protein were taken up by memory like CD4 T cells or acti-
vated lymphocytes including CD4 and CD8 T cells or B cells with higher efficiency relative to
these cells in their resting state. This preference would have the advantage of modulating
Fig 6. Protein delivery efficiency of dNP2 and TAT in various immune cells in vivo. (A) Experimental scheme is indicated. EGFP,
TAT-EGFP, dNP2-EGFP, or PBS (5 mg) were injected to 6-week-old C57BL/6 mice and after 1 h the splenocytes were isolated and
analyzed by flow cytometry after cell surface marker staining. (B-C) Protein delivery efficiency into Ly6C+CD11bhigh monocytes (red),
F4/80highCD11bint macrophage cells (blue), and Ly6G+CD11bhigh neutrophils (orange) was analyzed by flow cytometry. (D-E) Protein
delivery efficiency into CD8-Siglec H- myeloid DCs (red), CD8+Siglec H- lymphoid DCs (blue), and Siglec H+ pDC (orange) was analyzed
by flow cytometry. (F-G) Protein delivery efficiency into CD4+CD62LhighCD44low, CD4+CD62LlowCD44high, CD8+CD62LhighCD44low, or
CD8+CD62LlowCD44high cells was analyzed by flow cytometry. Bar graphs indicate the mean ± s.d. and within groups (EGFP,
TAT-EGFP, dNP2-EGFP) the differences of means of each cell types were compared with each other by two-way ANOVA with Tukey’s
multiple comparison test, * indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, **** indicates p<0.0001 (n = 3).
doi:10.1371/journal.pone.0155689.g006
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activated lymphocytes and memory T and B cells by delivering signaling modulatory mole-
cules. Previously we have attempted to deliver cytoplasmic domain of CTLA-4 protein which
inhibits T cell receptor signaling pathway in activated T cells modulated abnormal immune
responses in allergic or autoimmune disease models [18, 21, 47]. In addition, CPP-conjugated
Foxp3 protein could modulated OVA-induced allergic T cell responses in vivo without affect-
ing the other T cells response to KLH antigen which was still intact [12]. Other previous report
showed that CPP-based antisense-oligomer delivery successfully modulated T cell response by
altering gene expression [48]. These results suggest CPPs such as dNP2 and TAT could be
applied to modulate activated lymphocyte reaction by passive targeting or preference moiety.
In consistency of relative preference on activated T cells, regulatory T cells which is highly
expressing CD44, that could be regarded as activated/effector regulatory T cell [49], showed
significantly higher CPP-protein uptake efficiency than resting regulatory T cells which have
lower level of CD44. Regulatory T cell subsets were reported as CD45RA+Foxp3low resting reg-
ulatory T cells, CD45RA-Foxp3high activated regulatory T cells and CD45RA-Foxp3low nonsup-
pressive T cells [50]. In the case of carcinoma patients, the activated regulatory T cells are
increased in the peripheral circulation and antitumor immunity is suppressed [51]. The CPP-
drugs could be preferably delivered into activated regulatory T cells for cancer therapy which
possibly be a novel approach for cancer-immunotherapy.
Collectively, we demonstrate cell type preference of CPP delivery efficiency using dNP2 and
TAT in various immune cells in vitro and in vivo. First, CPP delivery efficiency is the highest
into phagocytic cells, especially lymphoid DCs. Second, CPP delivery efficiency is much higher
into the activated immune cells than non-activated immune cells. Last, in vivo protein delivery
efficiency of TAT is as little as negative control suggesting significant advantage of dNP2 usage
in vivo. These findings suggest that heterogeneity of CPP-protein delivery efficiency would be
dependent on cells own character such as phagocytic activity, etc. Cell type preference analysis
in non-immune cells also should be considered and it would provide important additional
information for the accurate application of CPPs in appropriate target cells.
Supporting Information
S1 Fig. One-way ANOVA with Sidak’s multiple comparison test results of Fig 1B–1D.
(TIF)
S2 Fig. Time dependent protein delivery efficiency of CPP-EGFPs in various immune cells.
5 μM of EGFP, TAT-EGFP, dNP2-EGFP or PBS were treated to splenocytes from 6-week-old
C57BL/6 mice for various reaction times including 10 min, 30 min, 1 h, 2 h or 6 h and protein
delivery efficiencies were analyzed by flow cytometry after cell staining with cell type specific
markers (CD4+ CD4 T cells, CD19+ B cells, NK1.1+ NK cells, CD11clowCD11bhighF4/80+ mac-
rophages, and MHCII+CD11chigh DCs). The values were normalized with the mean fluores-
cence intensity (MFI) of PBS treated samples (relative MFI). The graphs indicate the mean ± s.
d. In the case of TAT-EGFP and dNP2-EGFP, macrophages and DCs showed significantly
higher delivery efficiency than lymphocytes within every time points. We performed statistical
analysis by two-way ANOVA with Tukey’s multiple comparisons test and  indicates
p<0.001 and  indicates p<0.0001.
(TIF)
S3 Fig. Protein delivery efficiency of CPP-EGFPs into FACS sorted various immune cells.
5 μM of EGFP, TAT-EGFP, dNP2-EGFP or PBS were treated to FACS sorted CD4 T cells
(CD4+), CD8 T cells (CD8+), B cells (CD19+), Dendritic cells (MHCII+CD11chigh) or Macro-
phages (CD11clowCD11bhighF4/80+). The delivery efficiencies were analyzed by flow
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cytometry. In the bar graphs, the values were normalized with MFI of PBS treated samples (rel-
ative MFI).
(TIF)
Acknowledgments
This work was supported by grants the Korea Health Technology R&D project through the
Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health &
Welfare, Republic of Korea (HI14C0234 to J.M.C., HI14C2680 to S.J.H.) URL; http://www.
khidi.or.kr/eps. The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Author Contributions
Conceived and designed the experiments: JMC JL. Performed the experiments: SL JL JHK.
Analyzed the data: SL JL JHK TGK SJH JMC. Contributed reagents/materials/analysis tools:
TGK SJH. Wrote the paper: SL JMC.
References
1. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: frommolecular mechanisms to
therapeutics. British journal of pharmacology. 2009; 157(2):195–206. doi: 10.1111/j.1476-5381.2009.
00057.x PMID: 19309362; PubMed Central PMCID: PMC2697800.
2. van den Berg A, Dowdy SF. Protein transduction domain delivery of therapeutic macromolecules. Cur-
rent opinion in biotechnology. 2011; 22(6):888–93. doi: 10.1016/j.copbio.2011.03.008 PMID:
21489777.
3. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell.
1988; 55(6):1189–93. PMID: 2849510.
4. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically
active protein into the mouse. Science. 1999; 285(5433):1569–72. PMID: 10477521.
5. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain
translocates through biological membranes. The Journal of biological chemistry. 1994; 269(14):10444–
50. PMID: 8144628.
6. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell.
1997; 88(2):223–33. PMID: 9008163.
7. Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, et al. Conjugation of arginine
oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nature medicine.
2000; 6(11):1253–7. doi: 10.1038/81359 PMID: 11062537.
8. Uchida T, Kanazawa T, Kawai M, Takashima Y, Okada H. Therapeutic effects on atopic dermatitis by
anti-RelA short interfering RNA combined with functional peptides Tat and AT1002. The Journal of
pharmacology and experimental therapeutics. 2011; 338(2):443–50. doi: 10.1124/jpet.111.180042
PMID: 21531792.
9. Moschos SA, Williams AE, Lindsay MA. Cell-penetrating-peptide-mediated siRNA lung delivery. Bio-
chemical Society transactions. 2007; 35(Pt 4):807–10. doi: 10.1042/BST0350807 PMID: 17635153.
10. Freire JM, Veiga AS, Rego de Figueiredo I, de la Torre BG, Santos NC, Andreu D, et al. Nucleic acid
delivery by cell penetrating peptides derived from dengue virus capsid protein: design and mechanism
of action. The FEBS journal. 2014; 281(1):191–215. doi: 10.1111/febs.12587 PMID: 24286593.
11. Choi JM, Sohn JH, Park TY, Park JW, Lee SK. Cell permeable NFAT inhibitory peptide Sim-2-VIVIT
inhibits T-cell activation and alleviates allergic airway inflammation and hyper-responsiveness. Immu-
nology letters. 2012; 143(2):170–6. doi: 10.1016/j.imlet.2012.01.016 PMID: 22342853.
12. Choi JM, Shin JH, Sohn MH, Harding MJ, Park JH, Tobiasova Z, et al. Cell-permeable Foxp3 protein
alleviates autoimmune disease associated with inflammatory bowel disease and allergic airway inflam-
mation. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107
(43):18575–80. doi: 10.1073/pnas.1000400107 PMID: 20937878; PubMed Central PMCID:
PMC2972952.
Cell Type Preference of dNP2 and TAT in Various Immune Cells
PLOS ONE | DOI:10.1371/journal.pone.0155689 May 17, 2016 14 / 17
13. Lee J, Sayed N, Hunter A, Au KF, WongWH, Mocarski ES, et al. Activation of innate immunity is
required for efficient nuclear reprogramming. Cell. 2012; 151(3):547–58. doi: 10.1016/j.cell.2012.09.
034 PMID: 23101625; PubMed Central PMCID: PMC3506423.
14. Gump JM, June RK, Dowdy SF. Revised role of glycosaminoglycans in TAT protein transduction
domain-mediated cellular transduction. The Journal of biological chemistry. 2010; 285(2):1500–7. doi:
10.1074/jbc.M109.021964 PMID: 19858185; PubMed Central PMCID: PMC2801275.
15. Ziegler A. Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and
glycosaminoglycans. Advanced drug delivery reviews. 2008; 60(4–5):580–97. doi: 10.1016/j.addr.
2007.10.005 PMID: 18045730.
16. De Coupade C, Fittipaldi A, Chagnas V, Michel M, Carlier S, Tasciotti E, et al. Novel human-derived
cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules. The Biochemical
journal. 2005; 390(Pt 2):407–18. doi: 10.1042/BJ20050401 PMID: 15859953; PubMed Central PMCID:
PMC1198920.
17. Duchardt F, Ruttekolk IR, VerdurmenWP, Lortat-Jacob H, Burck J, Hufnagel H, et al. A cell-penetrating
peptide derived from human lactoferrin with conformation-dependent uptake efficiency. The Journal of
biological chemistry. 2009; 284(52):36099–108. doi: 10.1074/jbc.M109.036426 PMID: 19858187;
PubMed Central PMCID: PMC2794725.
18. Choi JM, Ahn MH, ChaeWJ, Jung YG, Park JC, Song HM, et al. Intranasal delivery of the cytoplasmic
domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation. Nature
medicine. 2006; 12(5):574–9. doi: 10.1038/nm1385 PMID: 16604087.
19. Lim S, KimWJ, Kim YH, Choi JM. Identification of a novel cell-penetrating peptide from human phos-
phatidate phosphatase LPIN3. Mol Cells. 2012; 34(6):577–82. doi: 10.1007/s10059-012-0284-y PMID:
23263658; PubMed Central PMCID: PMCPMC3887828.
20. Koo JH, Yoon H, KimWJ, Lim S, Park HJ, Choi JM. Cell membrane penetrating function of the nuclear
localization sequence in human cytokine IL-1alpha. Molecular biology reports. 2014; 41(12):8117–26.
doi: 10.1007/s11033-014-3711-7 PMID: 25205122.
21. Lim S, KimWJ, Kim YH, Lee S, Koo JH, Lee JA, et al. dNP2 is a blood-brain barrier-permeable peptide
enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis. Nature
communications. 2015; 6:8244. doi: 10.1038/ncomms9244 PMID: 26372309; PubMed Central PMCID:
PMC4579786.
22. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nature reviews Immunology. 2002; 2
(3):151–61. doi: 10.1038/nri746 PMID: 11913066.
23. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of den-
dritic cells and their subsets in the steady state and the inflamed setting. Annual review of immunology.
2013; 31:563–604. doi: 10.1146/annurev-immunol-020711-074950 PMID: 23516985; PubMed Central
PMCID: PMC3853342.
24. Mildner A, Jung S. Development and function of dendritic cell subsets. Immunity. 2014; 40(5):642–56.
doi: 10.1016/j.immuni.2014.04.016 PMID: 24837101.
25. Granucci F, Ferrero E, Foti M, Aggujaro D, Vettoretto K, Ricciardi-Castagnoli P. Early events in den-
dritic cell maturation induced by LPS. Microbes and infection / Institut Pasteur. 1999; 1(13):1079–84.
PMID: 10572310.
26. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through
the plasmamembrane and accumulates in the cell nucleus. The Journal of biological chemistry. 1997;
272(25):16010–7. PMID: 9188504.
27. Lee SH, Castagner B, Leroux JC. Is there a future for cell-penetrating peptides in oligonucleotide deliv-
ery? European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft
fur Pharmazeutische Verfahrenstechnik eV. 2013; 85(1):5–11. doi: 10.1016/j.ejpb.2013.03.021 PMID:
23958313.
28. Vives E, Schmidt J, Pelegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochimica
et biophysica acta. 2008; 1786(2):126–38. doi: 10.1016/j.bbcan.2008.03.001 PMID: 18440319.
29. Regberg J, Srimanee A, Langel U. Applications of cell-penetrating peptides for tumor targeting and
future cancer therapies. Pharmaceuticals. 2012; 5(9):991–1007. doi: 10.3390/ph5090991 PMID:
24280701; PubMed Central PMCID: PMC3816645.
30. Nakase I, Konishi Y, Ueda M, Saji H, Futaki S. Accumulation of arginine-rich cell-penetrating peptides
in tumors and the potential for anticancer drug delivery in vivo. Journal of controlled release: official
journal of the Controlled Release Society. 2012; 159(2):181–8. doi: 10.1016/j.jconrel.2012.01.016
PMID: 22285548.
31. Martin P, del Hoyo GM, Anjuere F, Ruiz SR, Arias CF, Marin AR, et al. Concept of lymphoid versus
myeloid dendritic cell lineages revisited: both CD8alpha(-) and CD8alpha(+) dendritic cells are gener-
ated from CD4(low) lymphoid-committed precursors. Blood. 2000; 96(7):2511–9. PMID: 11001905.
Cell Type Preference of dNP2 and TAT in Various Immune Cells
PLOS ONE | DOI:10.1371/journal.pone.0155689 May 17, 2016 15 / 17
32. Leenen PJ, Radosevic K, Voerman JS, Salomon B, van Rooijen N, Klatzmann D, et al. Heterogeneity
of mouse spleen dendritic cells: in vivo phagocytic activity, expression of macrophage markers, and
subpopulation turnover. J Immunol. 1998; 160(5):2166–73. PMID: 9498754.
33. Ruedl C, Bachmann MF. CTL priming by CD8(+) and CD8(-) dendritic cells in vivo. Eur J Immunol.
1999; 29(11):3762–7. doi: 10.1002/(SICI)1521-4141(199911)29:11&#60;3762::AID-
IMMU3762&#62;3.0.CO;2-F PMID: 10556833.
34. Steinman RM, Inaba K. Myeloid dendritic cells. J Leukoc Biol. 1999; 66(2):205–8. PMID: 10449155.
35. den Haan JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells
in vivo. J Exp Med. 2000; 192(12):1685–96. PMID: 11120766; PubMed Central PMCID:
PMCPMC2213493.
36. Lim S, Koo JH, Choi JM. Use of Cell-Penetrating Peptides in Dendritic Cell-Based Vaccination. Immune
Netw. 2016; 16(1):33–43. doi: 10.4110/in.2016.16.1.33 PMID: 26937230; PubMed Central PMCID:
PMCPMC4770098.
37. Sun Y, Hu YH. Cell-penetrating peptide-mediated subunit vaccine generates a potent immune
response and protection against Streptococcus iniae in Japanese flounder (Paralichthys olivaceus).
Veterinary immunology and immunopathology. 2015; 167(3–4):96–103. doi: 10.1016/j.vetimm.2015.
07.008 PMID: 26232860.
38. Sakuma S, Suita M, Inoue S, Marui Y, Nishida K, Masaoka Y, et al. Cell-penetrating peptide-linked poly-
mers as carriers for mucosal vaccine delivery. Molecular pharmaceutics. 2012; 9(10):2933–41. doi: 10.
1021/mp300329r PMID: 22953762.
39. Kronenberg K, Brosch S, Butsch F, Tada Y, Shibagaki N, Udey MC, et al. Vaccination with TAT-antigen
fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania major. The
Journal of investigative dermatology. 2010; 130(11):2602–10. doi: 10.1038/jid.2010.171 PMID:
20574442.
40. Cho HI, Kim EK, Park SY, Lee SK, Hong YK, Kim TG. Enhanced induction of anti-tumor immunity in
human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein. Can-
cer letters. 2007; 258(2):189–98. doi: 10.1016/j.canlet.2007.08.023 PMID: 17931768.
41. Shibagaki N, Udey MC. Dendritic cells transduced with TAT protein transduction domain-containing
tyrosinase-related protein 2 vaccinate against murine melanoma. European journal of immunology.
2003; 33(4):850–60. doi: 10.1002/eji.200323709 PMID: 12672050.
42. Kim SG, Park MY, Kim CH, Sohn HJ, Kim HS, Park JS, et al. Modification of CEA with both CRT and
TAT PTD induces potent anti-tumor immune responses in RNA-pulsed DC vaccination. Vaccine. 2008;
26(50):6433–40. doi: 10.1016/j.vaccine.2008.08.072 PMID: 18812201.
43. Mitsui H, Inozume T, Kitamura R, Shibagaki N, Shimada S. Polyarginine-mediated protein delivery to
dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitu-
mor immunity. The Journal of investigative dermatology. 2006; 126(8):1804–12. doi: 10.1038/sj.jid.
5700335 PMID: 16645583.
44. Viehl CT, Becker-Hapak M, Lewis JS, Tanaka Y, Liyanage UK, Linehan DC, et al. A tat fusion protein-
based tumor vaccine for breast cancer. Annals of surgical oncology. 2005; 12(7):517–25. doi: 10.1245/
ASO.2005.06.028 PMID: 15889213.
45. Gordon S, Pluddemann A, Martinez Estrada F. Macrophage heterogeneity in tissues: phenotypic diver-
sity and functions. Immunological reviews. 2014; 262(1):36–55. doi: 10.1111/imr.12223 PMID:
25319326; PubMed Central PMCID: PMC4231239.
46. Epelman S, Lavine KJ, Randolph GJ. Origin and functions of tissue macrophages. Immunity. 2014; 41
(1):21–35. doi: 10.1016/j.immuni.2014.06.013 PMID: 25035951; PubMed Central PMCID:
PMC4470379.
47. Choi JM, Kim SH, Shin JH, Gibson T, Yoon BS, Lee DH, et al. Transduction of the cytoplasmic domain
of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis. Proceedings
of the National Academy of Sciences of the United States of America. 2008; 105(50):19875–80. doi:
10.1073/pnas.0805198105 PMID: 19066215; PubMed Central PMCID: PMC2604944.
48. Marshall NB, Oda SK, London CA, Moulton HM, Iversen PL, Kerkvliet NI, et al. Arginine-rich cell-pene-
trating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA
splicing. Journal of immunological methods. 2007; 325(1–2):114–26. doi: 10.1016/j.jim.2007.06.009
PMID: 17673254.
49. Lim HW, Broxmeyer HE, Kim CH. Regulation of trafficking receptor expression in human forkhead
box P3+ regulatory T cells. J Immunol. 2006; 177(2):840–51. PMID: 16818738.
50. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentia-
tion dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009; 30
(6):899–911. doi: 10.1016/j.immuni.2009.03.019 PMID: 19464196.
Cell Type Preference of dNP2 and TAT in Various Immune Cells
PLOS ONE | DOI:10.1371/journal.pone.0155689 May 17, 2016 16 / 17
51. SunW, Li WJ, Wu CY, Zhong H, WenWP. CD45RA-Foxp3high but not CD45RA+Foxp3low suppres-
sive T regulatory cells increased in the peripheral circulation of patients with head and neck squamous
cell carcinoma and correlated with tumor progression. J Exp Clin Cancer Res. 2014; 33:35. doi: 10.
1186/1756-9966-33-35 PMID: 24761979; PubMed Central PMCID: PMCPMC4022051.
Cell Type Preference of dNP2 and TAT in Various Immune Cells
PLOS ONE | DOI:10.1371/journal.pone.0155689 May 17, 2016 17 / 17
